OMGA News and Press, Omega Therapeutics Inc. From 11/15/22

Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work PR Newswire CAMBRIDGE, Mass. , Nov. 15, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic appr...

Omega Therapeutics press release ( NASDAQ: OMGA ): Q3 GAAP EPS of -$0.54 beats by $0.07 . Revenue of $0.6M beats by $0.5M . As of September 30, 2022, the Company had cash, cash equivalents and marketable securities totaling $148.3M. For further details se...

Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights PR Newswire First Patient Dosed in Phase 1/2 MYCHELANGELO ™ I Trial of OTX-2002 OTX-2002 Granted Orphan Drug Designation by U.S. FDA for the Tre...

Omega Therapeutics to Participate in the Jefferies London Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first syst...

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Omega Therapeutics' ( NASDAQ: OMGA ) OTX-2002 to treat hepatocellular carcinoma (HCC), a type of liver cancer. The company noted that the first patient was dosed in phase 1/2 trial...

Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma PR Newswire Phase 1/2 MYCHELANGELO™ I Clinical Trial Underway to Evaluate Safety, Tolerability and Preliminary Antitumor Activity of OTX-2002 ...

Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene PR Newswire OTX-2002 is the First-Ever Epigenomic Controller in a New Class ...

Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer PR Newswire OTX-2101 is the Second Development Candidate Arising from the Company's Pioneering OMEGA Epigenomic Programming™ Platform ...

Omega Therapeutics to Participate in Two Upcoming Investor Conferences PR Newswire CAMBRIDGE, Mass. , Sept. 26, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic ...

Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire CAMBRIDGE, Mass. , Sept. 6, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pionee...